Lab Literacy / What 'Metabolic Health' Actually Means in Lab Terms
9 min readThe phrase shows up everywhere. Supplement copy, podcast intros, news headlines — "metabolic health" has become a blanket label for feeling good, looking lean, and avoiding diabetes. But in the research that peptide studies draw on, it isn't a vibe. It's a checklist with numbers attached.
That checklist comes from the National Cholesterol Education Program's Adult Treatment Panel III (ATP III), published in 2001 and still the reference framework used in most metabolic-syndrome research. It defines five criteria. Meet three of them and the diagnosis is metabolic syndrome — a cluster of interconnected risk factors that, taken together, substantially raise the odds of cardiovascular disease and type 2 diabetes.
Understanding those criteria is what lets you read a peptide trial's enrollment numbers and understand who was actually in the room.
The ATP III framework doesn't rely on a single test. It looks at five measures, each with its own threshold, and asks how many a person crosses:
| Criterion | Threshold | Notes |
|---|---|---|
| Waist circumference | ≥102 cm (men) / ≥88 cm (women) | The tesamorelin trials used ≥95 cm (men) / ≥94 cm (women) as inclusion — slightly lower, reflecting their HIV-lipodystrophy population |
| Triglycerides | ≥150 mg/dL | Fasting; the atherogenic pattern that often accompanies low HDL |
| HDL cholesterol | <40 mg/dL (men) / <50 mg/dL (women) | Low HDL paired with high triglycerides is the signature dyslipidaemia of metabolic syndrome |
| Blood pressure | ≥130/85 mmHg | Either systolic or diastolic; not the ≥160/100 trial-exclusion line — this is a softer threshold |
| Fasting glucose | ≥100 mg/dL | The 2003 revision lowered this from 110 mg/dL to align with the updated prediabetes definition |
Three or more of these five, and the label is metabolic syndrome. The criteria are not weighted — each counts equally — and they are deliberately broad. The framework was designed for population-level risk stratification, not individual diagnosis, which is part of why it survives: it captures a pattern that any one marker would miss.
Among the five criteria, the lipid pair — elevated triglycerides alongside reduced HDL cholesterol — gets particular attention in peptide research because it is the pattern that improved most visibly in the tesamorelin trials.
This isn't arbitrary. The combination of high triglycerides and low HDL is recognised as the atherogenic dyslipidaemia of metabolic syndrome, and it reflects a specific metabolic state: the liver is overproducing very-low-density lipoprotein (VLDL) particles, which carry triglycerides into circulation, while simultaneously failing to maintain adequate HDL-mediated reverse cholesterol transport. The result is a blood lipid profile that actively promotes arterial plaque deposition.
In the tesamorelin data, the triglyceride reduction was a secondary endpoint that moved meaningfully — which is notable because triglycerides are historically harder to shift with intervention than LDL cholesterol. The improvement was consistent with the drug's mechanism (growth hormone affects lipid metabolism directly) and with the pattern that the ATP III framework flags as the lipid signature of metabolic dysfunction.
The ATP III criteria capture metabolic syndrome at the level of its consequences — high waist, high glucose, bad lipids. HOMA-IR goes one step upstream and measures the mechanism that connects many of them: insulin resistance.
HOMA-IR stands for Homeostatic Model Assessment of Insulin Resistance. It's calculated from two routine fasting blood draws — glucose and insulin — using the formula (fasting glucose in mg/dL × fasting insulin in µIU/mL) / 405. It doesn't require a clamp study or any specialised procedure. Just two numbers from the same morning bloodwork.
The SURMOUNT trials for tirzepatide tracked HOMA2-IR (a computer-modelled variant) at multiple timepoints as a secondary endpoint. The reduction was significant, consistent with the drug's effect on glycaemic control.
Interpreting the number requires context, because unlike glucose or blood pressure, there is no single universally agreed clinical cutoff. Research convention, however, has settled on a practical tiered system:
| HOMA-IR Range | Interpretation |
|---|---|
| <1.0 | Optimal insulin sensitivity |
| 1.0–1.9 | Normal range |
| 2.0–2.5 | Early insulin resistance — the threshold most commonly used in research as a signal |
| ≥4.0 | Significant insulin resistance |
The 2.0–2.5 band is where researchers look when they want to identify a population that is metabolically heading in the wrong direction but hasn't yet crossed into frank diabetes. It's the zone the SURMOUNT non-diabetic arm was designed around: participants with BMI ≥30 but HbA1c below 6.5% — metabolically at risk but not yet diabetic. Many of those participants would have had HOMA-IR values in this early-resistance band.
High-sensitivity C-reactive protein (hs-CRP) is a marker of systemic inflammation produced by the liver in response to inflammatory signals. It's not specific to any one disease process — it rises with infection, injury, and chronic low-grade inflammation alike — which makes it a useful population-level risk barometer but a noisy individual one.
The American Heart Association and CDC published a joint risk stratification that researchers still reference:
| hs-CRP Level | CVD Risk Category |
|---|---|
| <1.0 mg/L | Low risk |
| 1.0–3.0 mg/L | Moderate risk |
| >3.0 mg/L | High risk |
There's an important caveat the AHA/CDC guidance flags: a value above 10 mg/dL likely reflects an acute inflammatory event (infection, recent injury, trauma) rather than chronic baseline risk. The recommendation in that case is to wait and retest, not to act on the number.
In peptide research, hs-CRP serves dual duty. It is a baseline risk marker — participants with elevated hs-CRP represent a higher-risk population, and some anti-inflammatory peptide research uses hs-CRP reduction as a secondary endpoint. The value isn't in a single reading but in the trend: does systemic inflammation come down over the course of the trial?
The ATP III criteria, HOMA-IR, and hs-CRP aren't three separate frameworks. They describe overlapping aspects of the same underlying state.
Insulin resistance (HOMA-IR ≥2.0) drives the glucose and triglyceride elevations that feed two of the five ATP III criteria. Systemic inflammation (hs-CRP >3.0) both reflects and accelerates the metabolic dysfunction that produces the other criteria. Central adiposity — the waist circumference that anchors the ATP III set — is both a cause and a consequence of the same metabolic loop.
When a trial reports that its participants had "metabolic syndrome" or were "metabolically at risk," it usually means enough of these markers crossed their thresholds to qualify. When a trial reports improvements in "metabolic parameters," it means some of these numbers moved in the favourable direction. The specific numbers matter because they tell you which aspects of the syndrome actually changed — and which didn't.
"Metabolic health" in a trial protocol is not the same as "metabolic health" in a wellness article. The research version means specific markers at specific thresholds, measured under specific conditions (fasting, morning draws, standardised assays). When a trial enrols participants with HbA1c between 7% and 10%, that's the SUSTAIN diabetes arm — a fundamentally different metabolic population from the SURMOUNT non-diabetic arm that required HbA1c below 6.5%.
The buzzword compresses all of this into two words. The lab numbers uncompress it. If a study's conclusion depends on a metabolic-health framing, check which of these criteria the participants actually met. The answer changes what the results mean.
This article is for educational purposes and is not medical advice. It does not recommend any test, compound, or protocol. Decisions about medical testing and treatment belong with a qualified clinician who knows your history.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.